azacitidine and abt-348

azacitidine has been researched along with abt-348 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albert, DH; Ansell, P; Arellano, M; Garcia-Manero, G; Kadia, T; Kantarjian, H; Khoury, HJ; Knight, EA; McKee, MD; Munasinghe, W; Oliver, B; Qin, Q; Ricker, JL; Roberts-Rapp, L; Tibes, R; Xiong, H	1

Trials

1 trial(s) available for azacitidine and abt-348

Article	Year
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Investigational new drugs, 2015, Volume: 33, Issue:4 Topics: Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Azacitidine; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor	2015

Article

Year

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Investigational new drugs, 2015, Volume: 33, Issue:4

Topics: Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Azacitidine; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor

2015